Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) EVP Thomas Bartrum sold 2,252 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $41,481.84. Following the transaction, the executive vice president now directly owns 103,862 shares in the company, valued at $1,913,138.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Privia Health Group Price Performance
Shares of NASDAQ:PRVA traded up $0.38 during midday trading on Thursday, reaching $18.41. The company had a trading volume of 782,205 shares, compared to its average volume of 940,409. The stock's fifty day moving average price is $19.67 and its 200-day moving average price is $21.16. The stock has a market capitalization of $2.18 billion, a P/E ratio of 96.90, a PEG ratio of 2.51 and a beta of 0.81. Privia Health Group, Inc. has a one year low of $17.54 and a one year high of $30.15.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). The company had revenue of $440.80 million during the quarter, compared to the consensus estimate of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The firm's quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. As a group, sell-side analysts forecast that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.
Institutional Trading of Privia Health Group
Institutional investors have recently added to or reduced their stakes in the business. Park Place Capital Corp increased its stake in Privia Health Group by 115.4% during the first quarter. Park Place Capital Corp now owns 2,492 shares of the company's stock valued at $49,000 after purchasing an additional 1,335 shares during the last quarter. Benjamin Edwards Inc. increased its stake in Privia Health Group by 44.9% during the fourth quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company's stock valued at $75,000 after purchasing an additional 1,003 shares during the last quarter. Covestor Ltd increased its stake in Privia Health Group by 8.3% during the third quarter. Covestor Ltd now owns 6,703 shares of the company's stock valued at $154,000 after purchasing an additional 514 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in Privia Health Group during the fourth quarter valued at $158,000. Finally, International Assets Investment Management LLC increased its stake in Privia Health Group by 2,721.7% during the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company's stock valued at $164,000 after purchasing an additional 6,886 shares during the last quarter. Institutional investors own 94.48% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have weighed in on PRVA. TD Cowen reduced their price target on shares of Privia Health Group from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, March 1st. UBS Group dropped their price objective on shares of Privia Health Group from $31.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, March 1st. Stifel Nicolaus dropped their price objective on shares of Privia Health Group from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday. Canaccord Genuity Group dropped their price objective on shares of Privia Health Group from $41.00 to $37.00 and set a "buy" rating on the stock in a research note on Tuesday, March 19th. Finally, Truist Financial dropped their price objective on shares of Privia Health Group from $32.00 to $28.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27.62.
Read Our Latest Research Report on PRVA
About Privia Health Group
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
